Latest Medtech News
Asia’s MedTech funding activity spanned advanced ultrasound, brain-computer interfaces and wearable rehabilitation, with Chinese and South Korean companies securing capital for technology development and international expansion. Separately, Stryker’s $400M investment in CMR Surgical marked the week’s largest deal, combining significant capital with a route to future acquisition and global expansion for Versius. Read more below.
As an executive search partner to the MedTech industry, Guided Solutions keeps a close eye on stories like these. Subscribe to our Industry Insights for weekly coverage.
Stryker invests $400M in CMR Surgical and secures option to acquire the company
Stryker will invest approximately $400M in CMR Surgical to accelerate innovation and global expansion of its Versius surgical robotics portfolio. The agreement also makes Stryker the exclusive U.S. sales agent for Versius and gives it an exclusive option to acquire CMR Surgical in full in the future, subject to the agreement’s terms.
CEO of CMR Surgical Massimiliano Colella: “This strategic alliance is a significant milestone for CMR and a strong endorsement of the technology, clinical experience and global business we have built,”
Krinwave raises RMB 400M to advance deep-penetration ultrasound imaging
Chinese medtech startup Krinwave has raised RMB 400M ($59.8M), with new investment from XVC and Sequoia China and increased backing from existing investors Sherpa and Tencent. The funding will support its kOS ultrasound imaging platform, which combines deep tissue penetration with super-resolution imaging to explore diagnostic applications across the brain, spine, gastrointestinal tract and lungs.
Founder and CEO Jiajia Liu
Frontier Brain-Inspired raises RMB 250M in angel funding to advance BCI technology
China-based Chengdu Frontier Brain-Inspired Artificial Intelligence Innovation Center Co., Ltd. has secured RMB 250M ($37.3M) in angel funding, backed by a subsidiary of Shanghai Pharmaceuticals Group and regional investment entities. The funding will support in-house BCI chip development, clinical trials and regulatory submissions for medical devices, mass production of brain-health headphones, and further development of AI models for brain health.
Chairman and Director Feng Rui
Sava Technologies raises $36M to advance next-generation glucose monitoring
London-based Sava Technologies has raised $36M in Series B funding led by Ascensia Diabetes Care, bringing its total funding to $68M. The investment will support manufacturing scale-up and preparations for launch of its continuous glucose monitor, which uses shorter microsensors designed to reduce skin disruption. Ascensia will hold exclusive commercialisation and distribution rights in Europe.
Co-Founders & Co-CEOs Renato Circi and Rafaël Michali
Hurotics raises KRW 25B Series A to expand wearable rehabilitation robots
South Korean startup Hurotics has raised KRW 25B ($18.8M) in Series A funding, led by Atinum Investment, with participation from existing and new strategic investors including Daewoong, Naver and Lotte. The funding will support overseas certification and distribution of its H-Medi soft exosuit for gait rehabilitation, as well as development and mass production of H-Care, designed to assist walking in everyday life.
CEO Ki-wook Lee: “With this investment, we will accelerate the global expansion of H-Medi and the commercialization of H-Care, and we will introduce wearable robots that combine physical AI to help people look after their health in daily life.”
NeuroGyn raises CHF 4M Series A to advance pelvic neuromodulation platform
Swiss medtech company NeuroGyn has raised CHF 4M ($4.8M) in Series A funding, led by a Swiss institutional investor active in medical technology, alongside private investors. The funding will support human clinical studies and regulatory development of its PosStim™ neuromodulation platform, initially targeting overactive bladder through a minimally invasive approach to pelvic nerve stimulation.
Founder Professor Marc Possover: "This financing allows us to take PosStim into human clinical studies and generate the evidence needed to assess its potential to make pelvic neuromodulation accessible to many more women,”
Nami Surgical raises £3.4M to advance robotic surgery technology
Nami Surgical has secured £3.4M ($4.5M) in funding, led by a £2M ($2.6M) investment from the Scottish National Investment Bank, with continued backing from existing investors. The funding will support the commercialisation of its miniaturised ultrasonic scalpel, which enables tissue cutting and blood vessel sealing within robotic surgical systems, and the expansion of its engineering team.
CEO Nikki Palfrey: “This investment gives us the resources to accelerate that journey, strengthening our engineering team in Glasgow while continuing to generate the evidence and relationships required for commercial adoption.”
The Phage raises ¥570M to advance AI-powered preventive medicine
Japanese healthtech company The Phage has raised ¥570M ($3.6M) in Series A funding, led by Itochu Technology Ventures, with participation from Tokio Marine & Nichido Fire Insurance and Fukui Capital Partners, alongside existing investors. The funding will advance its CGFM AI model, which learns from continuous glucose monitoring data to predict glucose fluctuations and assess health risks, and expand its personalised preventive medicine business.
Founder and CEO Shohei Tokunaga
Abrobo raises Series A+ funding to accelerate vascular robotics commercialization
Chinese medtech company Abrobo has completed a Series A+ financing round worth tens of millions of yuan, led by PU HE CAPITAL, with strategic follow-on investment from Longgang Financial Holdings. The funding will support expanded applications and commercialization of its PANVIS vascular intervention robotics platform, alongside R&D and regulatory registration for automated and remote surgical systems.
Founder Professor Shuxiang Guo
Sharp Biomedical secures pre-seed funding to advance outpatient spine care
Sharp Biomedical has closed a pre-seed funding round led by gener8tor 1889, with participation from physician angel investors. The funding will support development and testing of its first purpose-built toolset and implant system, designed to help outpatient pain clinics treat early-to-mid-stage chronic pain through simplified, manual spine procedures.
Founder and CEO Dan Newman: "This pre-seed funding allows us to empower physicians with simple, safe, and reliable procedures - giving clinics advanced intervention capabilities without the burden of massive capital demands."
